Welcome!

News Feed Item

Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies

Alabama Supreme Court decision is an important win for patients in cases involving prescription drugs

BIRMINGHAM, Ala., Aug. 19, 2014 /PRNewswire/ -- The Alabama Supreme Court, in a 6-3 decision on August 15, 2014, re-affirmed that patients can sue drug makers who mislead doctors into believing that prescription medicines the companies market do not cause harmful side‑effects.  The case is Weeks v. Wyeth, and the decision came after the Supreme Court ruled against the drug makers in that same case last year. Heninger Garrison Davis attorneys Lew Garrison and Chris Hood represent the patient in the case, Danny Weeks.

The decision won a clear majority of the Alabama Supreme Court. Six of the nine justices voted for it. Associate Justice Michael F. Bolin authored the decision, joined by Associate Justices Stuart, Main, Wise, and Bryan, and including Associate Justice Shaw, who fully concurred and specially wrote to address responses to the earlier decision in the case.

Weeks' attorney Lew Garrison stated, "We agree with the decision, and we're very pleased that Danny and his wife Vicki will get their day in court. It's a victory for patients." Mr. Weeks was hurt by the brand makers of the drug Reglan, according to the suit.

The decision allows patients injured by prescription drugs to sue when their doctors are deceived, including when a pharmacist fills the prescription with a generic replica of the prescribed drug.  Mr. Weeks received a generic replica of Reglan, as allowed by law. The law allowing the substitution, in Alabama and in all other states, requires the federal Food and Drug Administration to first approve the generic tablet as a bioequivalent replacement for the brand name drug. The substitution ensures that the patient receives the same medicine, not a different medicine. The makers of the branded drug furnish the information about it and are responsible by law for the information, including updating it to warn of significant risks to patients. The U.S. Supreme Court clearly confirmed that responsibility of branded drug companies in PLIVA v. Mensing, a landmark decision in 2011.

The facts of generic substitution for branded drugs are foreseeable and well known by everyone who works with prescription medicines -- doctors, pharmacists, and the brand defendants in the Weeks case. The brand defendants made Reglan and, according to the lawsuit, created the information about it which misled Danny Week's doctor, leading to the severe injury.

Weeks suffered a permanent and disabling neurological injury. He alleges that doctors who prescribed the brand drug were misled about the side-effects, and the deceit hurt him.

National media have covered the case. The Wall Street Journal, in reporting the first decision in it last year, explained the allegation that Weeks' doctor "relied on the representations made by the name brand manufacturer to assess the risks [of the drug]." The WSJ reported that "[a] brand name manufacturer could 'reasonably foresee' that a physician would rely on its warning label 'even if the patient ultimately consumed the generic version of the drug,' Justice Bolin wrote."

This victory for patients also is positive for doctors, who are owed a duty of truth by companies which promote the drugs the doctors prescribe. "Telling the truth about these drugs allows doctors to make good choices about which medicines to prescribe," according to Weeks' other attorney, Chris Hood.  "When the truth is concealed, patients are hurt, which happened here."

The decision for Weeks is not an outlier, contrary to the view of some commentators. It rests on settled Alabama law, and other courts have ruled the same way, including the federal court which certified the question to the Alabama Supreme Court. Three other federal courts applying the laws of other states likewise have ruled against branded drug companies in favor of patients hurt by generic substitute drugs. Three state appeals courts have addressed the same question, and two of them -- in California and now in Alabama -- sided with the patients against makers of the brand drug.  Alabama thus joins a number of other state and federal courts which permit this type of suit.

The similar federal decisions are recent.  They are Colas v. Abbvie, Inc., 2014 WL 2699756 at *3 (N.D. Ill. June 13, 2014) (ruling under Virginia law for a patient who, like Danny Weeks, was dispensed a generic substitute drug and sued a brand defendant for fraud); Dolin v. SmithKline Beecham Corp., 2014 WL 804458 (N.D. Ill. Feb. 28, 2014) (ruling under Illinois law for a generic‑ingesting patient against brand defendant), mandamus denied, In re GlaxoSmithKline, LLC, 2014 WL 2506461 (7th Cir. June 4, 2014); Kellogg v. Wyeth, 762 F. Supp. 2d 694, 700 (D. Vt. 2010) (ruling under Vermont law for a generic‑ingesting patient against brand defendant).

The California decision in favor of patients is Conte v. Wyeth, Inc., 168 Cal. App. 4th 89, 85 Cal. Rptr. 3d 299 (2008) (ruling for a generic-ingesting patient under California law).  The  other state appellate decision on the question is Huck v. Wyeth, Inc., 2014 WL 3377071 (Iowa July 11, 2014), which was decided for the branded drug companies.  Huck is a plurality decision, not a majority opinion, so it is not precedent even for Iowa courts, according to the Iowa Supreme Court.  Audubon‑Exira Ready Mix, Inc. v. Illinois Cent. Gulf R. Co., 335 N.W.2d 148, 151 (Iowa 1983)  (plurality decisions are not precedent).

W. Lewis Garrison, Jr., is a senior partner of Heninger Garrison Davis, LLC, headquartered in Birmingham, Alabama, and Christopher B. Hood is an associate attorney of HGD.  They represent Danny and Vicki Weeks.  HGD has offices in Atlanta, Birmingham, Los Angeles, New Jersey, New York, and metropolitan Washington, D.C.  Our attorneys are leaders in national cases involving prescription drugs and medical devices.

Contact:
Stacy Smith
[email protected]
Heninger Garrison Davis
2224 1st Avenue North
Birmingham, Alabama 35203
(205) 326-3336

SOURCE Heninger Garrison Davis, LLC

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Infoblox delivers Actionable Network Intelligence to enterprise, government, and service provider customers around the world. They are the industry leader in DNS, DHCP, and IP address management, the category known as DDI. We empower thousands of organizations to control and secure their networks from the core-enabling them to increase efficiency and visibility, improve customer service, and meet compliance requirements.
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, will describe how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launchi...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, will go over the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, applicatio...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous a...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, will lead you through the exciting evolution of the cloud. He'll look at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering ...
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...